The Innovation Medicine > 2024 Vol. 2 > No. 1 > 100056
Next Article Previous Article
COMMENTARY   Open Access    

Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes

  • 1.

    Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

  • 2.

    Department of Pathology, Affiliated Tongren Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200336, China

  • 3.

    Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

  • 4.

    Laboratory of Targeted Therapy and Precision Medicine, Department of Clinical Laboratory, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

More Information
The Innovation Medicine  2(1),  https://doi.org/10.59717/j.xinn-med.2024.100056  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] André, F., Ciruelos, E., Rubovszky, G., et al. (2019). Alpelisib for-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. New Engl J Med 380(20): 1929−1940. DOI: 10.1056/NEJMoa1813904.

    View in Article CrossRef Google Scholar

    [2] Varkaris, A., Pazolli, E., Gunaydin, H., et al. (2024). Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov 14(2): 240−257. DOI: 10.1158/2159-8290.Cd-23-0944.

    View in Article CrossRef Google Scholar

    [3] Labrie, M., Brugge, J.S., Mills, G.B., et al. (2022). Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 22(6): 323−339. DOI: 10.1038/s41568-022-00454-5.

    View in Article CrossRef Google Scholar

    [4] Varkaris, A., Fece de la Cruz, F., Martin, E.E., et al. (2024). Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. Cancer Discov 14(2): 227−239. DOI: 10.1158/2159-8290.Cd-23-0704.

    View in Article CrossRef Google Scholar

    [5] Fan, Y. and Xu, B. (2023). CDK4/6 inhibition: What’s happening beyond CDK4/6 inhibition may also matter. The Innovation Medicine 1(2): 100016. DOI: 10.59717/j.xinn-med.2023.100016.

    View in Article CrossRef Google Scholar

    • CITED BY

  • Cite this article:

    Zhang Y., Duan J., Liu Y., et al., (2024). Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes. The Innovation Medicine 2(1): 100056. https://doi.org/10.59717/j.xinn-med.2024.100056
    Zhang Y., Duan J., Liu Y., et al., (2024). Breaking a bottleneck for on-target toxicity: A mutant-selective PI3Kα inhibitor finally comes. The Innovation Medicine 2(1): 100056. https://doi.org/10.59717/j.xinn-med.2024.100056

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(473) PDF downloads(212) Cited by(0)

Relative Articles

Article Contents
ABOUT THIS ARTICLE

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    Journal links

    {{newsColumn.name}}

    Stay connected

    Copyright © Innovation Press